Abstract 59P
Background
BC is a heterogeneous disease with variable clinical outcomes among patients with the same clinical and pathological characteristics, treated with similar treatment. Despite significant improvement in the outcomes, many of them acquire resistance to multiple anticancer drugs, leading to recurrence and /or metastasis. It remains an unmet need to identify robust molecular defects and novel biomarkers to adopt individualized treatment decisions in BC. CGP using next generation sequencing (NGS) provides more druggable gene aberrations at “one go” that includes somatic BRCA (sBRCA), homologous recombinant repair pathway alteration (HRR) and tumor agnostic markers like tumor mutation burden (TMB) and microsatellite instability (MSI) burden.
Methods
140 BC cases at HCG cancer centre were profiled using Illumina TruSight Oncology 500 assay on a NextSeq2000 in an IRB-approved study. The findings from NGS data were discussed in the molecular tumor board (MTB) and recommendations were documented for change in clinical management and follow-up.
Results
Clinically relevant variants were detected in 133/140 BC patients (95%) with actionable mutations in >80% cases with direct impact on therapy and constituted of 47% Tier 1 and 41% Tier 2 mutations. CGP revealed a multitude of genomic alterations such as PI3KCA/AKT/PTEN signalling pathway (32%) in HR+Her2- mBC and ESR1 mutation (7%) in HR+ mBC predictive of resistance to anti-Her2 and endocrine therapy respectively. 22 patients (16%) with sBRCA and HRR pathways alteration treated either with platinum / PARP inhibitors post platinum treatment were found to have partial-to-complete pathological response (pCR). 23 BC patients with high TMB (16%) were initiated on immunotherapy as a single drug or in combination with chemotherapy and are on follow up. The mutation spectrum, HRR pathway alterations and high TMB of triple- negative BC (TNBC) cases revealed a distinctive mutational profile with clinical utility in >95% cases.
Conclusions
Recommending CGP tests at a more appropriate time helps in modifying BC treatment protocol, clinical decisions and provides patients with greater benefit from targeted treatments based on their specific gene alterations and resistance mechanism.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Personal and Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract